Exacerbation Risk in Asthma

Completed

Conditions studied: Asthma

In brief

The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.

Key facts

Study ID

NCT05501639

Run by

Boehringer Ingelheim

People needed

1899

Starts

2021-05-14

Expected to finish

2021-11-02

Last updated by the study team

2024-04-01

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with least two asthma diagnosis
• Patients will be required to be concurrently on inhaled corticosteroids (ICS)+Tiotropium (tio) (specifically Tiotropium Respimat® 1.25 mcg) or ICS/LABA
• Patients will be required to have enrollment for at least 6 months prior to ICS+Tio or ICS/LABA use

You may not qualify if…

• Patients with least two diagnosis of chronic obstructive pulmonary disease (COPD) at any time during the study period
• Patients less than 12 years of age
• Patients on biologics within 6 months prior to ICS+Tio or ICS/LABA use
• Patients with prior Tio or ICS/LABA use during the 6-month baseline period
• Patients with urinary bladder obstruction, urinary retention, and glaucoma
• After the propensity score matching (PSM) process, unmatched patients

Where it is running

• eMax Health — White Plains, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.